109 related articles for article (PubMed ID: 8339217)
1. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen.
Matzkin H; Soloway MS; Schellhammer PF; Chodak G; Smith JA; Caplan R; Kennealey GT
Cancer; 1993 Aug; 72(4):1286-90. PubMed ID: 8339217
[TBL] [Abstract][Full Text] [Related]
2. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma.
Soloway MS; Matzkin H
Cancer; 1993 Feb; 71(3 Suppl):1083-8. PubMed ID: 8428332
[TBL] [Abstract][Full Text] [Related]
4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
5. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer.
Imamoto T; Suzuki H; Akakura K; Komiya A; Nakamachi H; Ichikawa T; Igarashi T; Ito H
Endocr J; 2001 Oct; 48(5):573-8. PubMed ID: 11789562
[TBL] [Abstract][Full Text] [Related]
7. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer.
Migliari R; Muscas G; Usai E
J Urol; 1992 Aug; 148(2 Pt 1):338-41. PubMed ID: 1378907
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
9. Prognostic factors in metastatic prostate cancer.
Matzkin H; Perito PE; Soloway MS
Cancer; 1993 Dec; 72(12 Suppl):3788-92. PubMed ID: 7504577
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
13. Casodex--mechanisms of action and opportunities for usage.
Blackledge G
Cancer; 1993 Dec; 72(12 Suppl):3830-3. PubMed ID: 7504578
[No Abstract] [Full Text] [Related]
14. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
17. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
[TBL] [Abstract][Full Text] [Related]
18. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
19. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
El-Gabry EA; Strup SE; Gomella LG
Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
[TBL] [Abstract][Full Text] [Related]
20. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
